Elicio Therapeutics, Inc. Research and Development Expense
Elicio Therapeutics, Inc. (ELTX) reported Research and Development Expense of $6.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Elicio Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $6.81M, a 2.78% decline year-over-year.
- Elicio Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $6.76M, a 13.13% decline year-over-year.
- Elicio Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $5.08M, a 52.56% decline year-over-year.
- Elicio Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $5.04M, a 30.09% decline year-over-year.
- Elicio Therapeutics, Inc. research and development expense for fiscal 2025 was $24.90M, a 26.01% decline from fiscal 2024.
- Elicio Therapeutics, Inc. research and development expense for fiscal 2024 was $33.66M, a 41.12% increase from fiscal 2023.
- Elicio Therapeutics, Inc. research and development expense for fiscal 2023 was $23.85M, a 31.74% increase from fiscal 2022.
- Elicio Therapeutics, Inc. research and development expense for fiscal 2022 was $18.10M, a 62.83% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.81M 10-Q · filed 2026-08-13 | $13.57M 10-Q · filed 2026-08-13 | $18.65M derived: sum of 3 quarters · filed 2026-08-13 | $23.69M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $6.76M 10-Q · filed 2026-05-11 | $11.84M derived: sum of 2 quarters · filed 2026-05-11 | $16.88M derived: sum of 3 quarters · filed 2026-05-11 | $23.88M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $10.12M derived: sum of 2 quarters · filed 2026-03-12 | $17.13M derived: sum of 3 quarters · filed 2026-08-13 | $24.90M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $5.04M 10-Q · filed 2025-11-13 | $12.04M derived: sum of 2 quarters · filed 2026-08-13 | $19.82M 10-Q · filed 2025-11-13 | $30.53M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $7.01M 10-Q · filed 2026-08-13 | $14.78M 10-Q · filed 2026-08-13 | $25.49M derived: sum of 3 quarters · filed 2026-08-13 | $32.70M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $7.78M 10-Q · filed 2026-05-11 | $18.49M derived: sum of 2 quarters · filed 2026-05-11 | $25.70M derived: sum of 3 quarters · filed 2026-05-11 | $33.88M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $10.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $17.92M derived: sum of 2 quarters · filed 2026-03-12 | $26.10M derived: sum of 3 quarters · filed 2026-03-12 | $33.66M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $7.21M 10-Q · filed 2025-11-13 | $15.39M derived: sum of 2 quarters · filed 2025-11-13 | $22.95M 10-Q · filed 2025-11-13 | $29.10M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $8.18M 10-Q · filed 2025-08-07 | $15.74M 10-Q · filed 2025-08-07 | $21.90M derived: sum of 3 quarters · filed 2025-08-07 | $29.16M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $7.56M 10-Q · filed 2025-05-13 | $13.72M derived: sum of 2 quarters · filed 2025-05-13 | $20.98M derived: sum of 3 quarters · filed 2025-05-13 | $25.92M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.42M derived: sum of 2 quarters · filed 2025-03-31 | $18.36M derived: sum of 3 quarters · filed 2025-03-31 | $23.85M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $7.26M 10-Q · filed 2024-11-13 | $12.21M derived: sum of 2 quarters · filed 2024-11-13 | $17.69M 10-Q · filed 2024-11-13 | $21.98M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $4.94M 10-Q · filed 2024-08-13 | $10.43M 10-Q · filed 2024-08-13 | $14.72M derived: sum of 3 quarters · filed 2024-08-13 | $19.31M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $5.48M 10-Q · filed 2024-05-15 | $326.00K 10-Q · filed 2023-05-10 | $9.77M derived: sum of 2 quarters · filed 2024-05-15 | $14.37M derived: sum of 3 quarters · filed 2024-05-15 | $19.41M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $8.88M derived: sum of 2 quarters · filed 2024-03-29 | $13.92M derived: sum of 3 quarters · filed 2024-03-29 | $18.10M 10-K · filed 2024-03-29 | $18.10M 10-K · filed 2023-03-17 | |||
| 2022-09-30 | $4.59M 10-Q · filed 2023-11-13 | $2.94M 10-Q · filed 2022-11-14 | $9.63M derived: sum of 2 quarters · filed 2023-11-13 | $13.81M 10-Q · filed 2023-11-13 | $17.94M 10-Q · filed 2022-11-14 | $27.97M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $5.04M 10-Q · filed 2023-08-14 | $6.07M 10-Q · filed 2022-08-15 | $9.22M 10-Q · filed 2023-08-14 | $17.74M 10-Q · filed 2022-08-15 | $23.38M derived: sum of 3 quarters · filed 2023-08-14 | $36.66M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $11.67M 10-Q · filed 2023-05-10 | $18.34M derived: sum of 2 quarters · filed 2023-05-10 | $31.62M derived: sum of 3 quarters · filed 2023-05-10 | $46.07M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $19.96M derived: sum of 2 quarters · filed 2023-03-17 | $34.40M derived: sum of 3 quarters · filed 2023-03-17 | $48.70M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $13.29M 10-Q · filed 2022-11-14 | $27.73M derived: sum of 2 quarters · filed 2022-11-14 | $42.03M 10-Q · filed 2022-11-14 | $53.09M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $14.44M 10-Q · filed 2022-08-15 | $28.74M 10-Q · filed 2022-08-15 | $39.81M derived: sum of 3 quarters · filed 2022-08-15 | $45.89M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $14.30M 10-Q · filed 2022-05-16 | $25.36M derived: sum of 2 quarters · filed 2022-05-16 | $31.45M derived: sum of 3 quarters · filed 2022-05-16 | $43.68M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $11.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $17.15M derived: sum of 2 quarters · filed 2022-03-30 | $29.38M derived: sum of 3 quarters · filed 2022-03-30 | $38.98M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $6.09M 10-Q · filed 2021-11-12 | $18.32M derived: sum of 2 quarters · filed 2021-11-12 | $27.91M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $12.23M 10-Q · filed 2021-08-12 | $21.83M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $9.60M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |